HRP20230809T1 - Liječenje alzheimerove bolesti u određenoj populaciji bolesnika - Google Patents
Liječenje alzheimerove bolesti u određenoj populaciji bolesnika Download PDFInfo
- Publication number
- HRP20230809T1 HRP20230809T1 HRP20230809TT HRP20230809T HRP20230809T1 HR P20230809 T1 HRP20230809 T1 HR P20230809T1 HR P20230809T T HRP20230809T T HR P20230809TT HR P20230809 T HRP20230809 T HR P20230809T HR P20230809 T1 HRP20230809 T1 HR P20230809T1
- Authority
- HR
- Croatia
- Prior art keywords
- subject
- treatment
- preparation
- use according
- valyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562216404P | 2015-09-10 | 2015-09-10 | |
| US201662290287P | 2016-02-02 | 2016-02-02 | |
| US201662302027P | 2016-03-01 | 2016-03-01 | |
| US201662365809P | 2016-07-22 | 2016-07-22 | |
| PCT/US2016/051091 WO2017044840A1 (en) | 2015-09-10 | 2016-09-09 | Methods of treating neurodegenerative disorders in a particular patient population |
| EP16845181.3A EP3347002B1 (en) | 2015-09-10 | 2016-09-09 | Treatment of alzheimer's disease in a particular patient population |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230809T1 true HRP20230809T1 (hr) | 2023-10-27 |
Family
ID=58240195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230809TT HRP20230809T1 (hr) | 2015-09-10 | 2016-09-09 | Liječenje alzheimerove bolesti u određenoj populaciji bolesnika |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11191742B2 (enExample) |
| EP (2) | EP4275750A3 (enExample) |
| JP (4) | JP6789579B2 (enExample) |
| KR (2) | KR102412997B1 (enExample) |
| CN (3) | CN108289870A (enExample) |
| AU (1) | AU2016319107B2 (enExample) |
| CA (1) | CA2997376C (enExample) |
| DK (1) | DK3347002T3 (enExample) |
| ES (1) | ES2952727T3 (enExample) |
| FI (1) | FI3347002T3 (enExample) |
| HR (1) | HRP20230809T1 (enExample) |
| HU (1) | HUE062511T2 (enExample) |
| LT (1) | LT3347002T (enExample) |
| MD (1) | MD3347002T2 (enExample) |
| MX (2) | MX392677B (enExample) |
| PL (1) | PL3347002T3 (enExample) |
| PT (1) | PT3347002T (enExample) |
| RS (1) | RS64481B1 (enExample) |
| SI (1) | SI3347002T1 (enExample) |
| SM (1) | SMT202300250T1 (enExample) |
| WO (1) | WO2017044840A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015230972B2 (en) | 2014-03-21 | 2021-05-27 | Alzheon, Inc. | Methods for treating neurological disorders |
| WO2017044840A1 (en) * | 2015-09-10 | 2017-03-16 | Alzheon, Inc. | Methods of treating neurodegenerative disorders in a particular patient population |
| CN114805211B (zh) | 2017-03-21 | 2024-08-23 | 润佳（苏州）医药科技有限公司 | 同位素富集3-氨基-1-丙磺酸衍生物、药物组合物及其用途 |
| CN110003058B (zh) | 2018-01-04 | 2022-01-25 | 润佳（苏州）医药科技有限公司 | 3-((l-缬氨酰基)氨基)-3,3-二氘-1-丙磺酸晶型、制备方法及用途 |
| PL3829568T3 (pl) * | 2018-08-01 | 2024-03-25 | Alzheon, Inc. | Pochodne kwasu sulfopropanowego do leczenia zaburzeń neurodegeneracyjnych |
| LT3829563T (lt) * | 2018-08-01 | 2025-02-25 | Alzheon, Inc. | 3-sulfopropano rūgštis neurodegeneracinėms ligoms gydyti |
| CN111170901A (zh) * | 2018-11-13 | 2020-05-19 | 润佳（苏州）医药科技有限公司 | 3-((l-缬氨酰基)氨基)-1-丙磺酸晶型、制备方法及其用途 |
| CN114269949A (zh) | 2019-06-17 | 2022-04-01 | 阿尔泽恩股份有限公司 | 用于治疗神经变性病症的方法 |
| CN112791078B (zh) | 2019-11-13 | 2022-12-06 | 润佳（苏州）医药科技有限公司 | 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途 |
| MX2024007070A (es) * | 2021-12-09 | 2024-08-22 | Alzheon Inc | Alz-801 para uso en el tratamiento de la enfermedad de alzheimer. |
| US20250127734A1 (en) * | 2022-02-07 | 2025-04-24 | Alzheon, Inc. | Alz-801 for use in treating a covid-19 associated neurological symptom |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| WO1994009155A1 (en) | 1992-10-13 | 1994-04-28 | Duke University | Methods of detecting alzheimer's disease |
| US20050031651A1 (en) | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| US20070010573A1 (en) | 2003-06-23 | 2007-01-11 | Xianqi Kong | Methods and compositions for treating amyloid-related diseases |
| US20050142191A1 (en) | 2003-06-23 | 2005-06-30 | Neurochem (International) Limited | Pharmaceutical formulations of amyloid inhibiting compounds |
| US20060079578A1 (en) | 2003-06-23 | 2006-04-13 | Julie Laurin | Pharmaceutical formulations of amyloid inhibiting compounds |
| WO2005060393A2 (en) | 2003-08-11 | 2005-07-07 | California Institute Of Technology | Microfluidic large scale integration |
| JP2008535907A (ja) * | 2005-04-12 | 2008-09-04 | ニユーロケム（インターナショナル）、リミテッド | アミロイド阻害化合物の薬学的製剤 |
| EP2862581B1 (en) | 2006-10-12 | 2021-08-11 | BHI Limited Partnership | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid |
| US20100183513A1 (en) | 2006-11-24 | 2010-07-22 | Wolfgang Froestl | N-(methyl) -1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimer's |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| EP2322163A1 (en) * | 2009-11-03 | 2011-05-18 | Pharnext | New therapeutics approaches for treating alzheimer disease |
| US20120009125A1 (en) | 2010-07-06 | 2012-01-12 | Lombard Jay L | Apoe4 and apoj biomarker-based prevention and treatment of dementia |
| DK2605655T3 (en) * | 2010-08-19 | 2019-02-04 | Buck Institute For Age Res | METHODS OF TREATING SMALL COGNITIVE DISABILITY (MCI) AND RELATED DISORDERS |
| WO2013168174A1 (en) * | 2012-05-08 | 2013-11-14 | Ramot At Tel-Aviv University Ltd. | Apoe4 antibodies for treatment of neurodegenerative conditions |
| JP6424210B2 (ja) * | 2013-05-06 | 2018-11-14 | バクスアルタ インコーポレイテッド | プールされた免疫グロブリンｇを用いたアルツハイマー病の亜集団の治療 |
| BR112016018170A2 (pt) | 2014-02-08 | 2018-02-20 | Genentech, Inc. | métodos para tratar doença de alzheimer |
| AU2015230972B2 (en) | 2014-03-21 | 2021-05-27 | Alzheon, Inc. | Methods for treating neurological disorders |
| WO2017044840A1 (en) * | 2015-09-10 | 2017-03-16 | Alzheon, Inc. | Methods of treating neurodegenerative disorders in a particular patient population |
-
2016
- 2016-09-09 WO PCT/US2016/051091 patent/WO2017044840A1/en not_active Ceased
- 2016-09-09 CN CN201680052760.4A patent/CN108289870A/zh active Pending
- 2016-09-09 JP JP2018512564A patent/JP6789579B2/ja active Active
- 2016-09-09 HU HUE16845181A patent/HUE062511T2/hu unknown
- 2016-09-09 SI SI201631729T patent/SI3347002T1/sl unknown
- 2016-09-09 AU AU2016319107A patent/AU2016319107B2/en active Active
- 2016-09-09 HR HRP20230809TT patent/HRP20230809T1/hr unknown
- 2016-09-09 PL PL16845181.3T patent/PL3347002T3/pl unknown
- 2016-09-09 MX MX2018003023A patent/MX392677B/es unknown
- 2016-09-09 RS RS20230603A patent/RS64481B1/sr unknown
- 2016-09-09 LT LTEPPCT/US2016/051091T patent/LT3347002T/lt unknown
- 2016-09-09 EP EP23176559.5A patent/EP4275750A3/en active Pending
- 2016-09-09 EP EP16845181.3A patent/EP3347002B1/en active Active
- 2016-09-09 SM SM20230250T patent/SMT202300250T1/it unknown
- 2016-09-09 KR KR1020187009381A patent/KR102412997B1/ko active Active
- 2016-09-09 KR KR1020227009418A patent/KR102547164B1/ko active Active
- 2016-09-09 ES ES16845181T patent/ES2952727T3/es active Active
- 2016-09-09 CA CA2997376A patent/CA2997376C/en active Active
- 2016-09-09 CN CN202310582394.5A patent/CN116712423A/zh active Pending
- 2016-09-09 CN CN202310582365.9A patent/CN116712422A/zh active Pending
- 2016-09-09 MD MDE20180700T patent/MD3347002T2/ro unknown
- 2016-09-09 DK DK16845181.3T patent/DK3347002T3/da active
- 2016-09-09 PT PT168451813T patent/PT3347002T/pt unknown
- 2016-09-09 FI FIEP16845181.3T patent/FI3347002T3/fi active
- 2016-09-09 US US15/758,405 patent/US11191742B2/en active Active
-
2018
- 2018-03-09 MX MX2022003128A patent/MX2022003128A/es unknown
-
2020
- 2020-09-28 JP JP2020161995A patent/JP7128536B2/ja active Active
-
2021
- 2021-09-17 US US17/477,886 patent/US20220096406A1/en not_active Abandoned
-
2022
- 2022-08-12 JP JP2022128786A patent/JP2022145949A/ja active Pending
-
2023
- 2023-09-06 US US18/462,238 patent/US20230414541A1/en active Pending
-
2025
- 2025-02-17 JP JP2025023627A patent/JP2025065545A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230809T1 (hr) | Liječenje alzheimerove bolesti u određenoj populaciji bolesnika | |
| HRP20200990T1 (hr) | Sastavi za poboljšanje stanične vijabilnosti i postupci za njihovu upotrebu | |
| JP2015038135A5 (enExample) | ||
| ES2988617T3 (es) | Norketotifeno para el tratamiento de la hipercitocinemia y las infecciones virales | |
| MX395710B (es) | Composiciones gomosas de multicomponentes con nucleo duro. | |
| HRP20240231T1 (hr) | Farmaceutske formulacije inhibitora brutonove tirozin kinaze | |
| HRP20150644T1 (hr) | Metoda za lijeäśenje atrijalne fibrilacije | |
| HRP20230300T1 (hr) | Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije | |
| HRP20171256T1 (hr) | Farmaceutski pripravci karbetocina | |
| HRP20161444T1 (hr) | Farmaceutski pripravci koji sadrže lokalni anestetik kao što je bupivakain za lokalnu primjenu u usta ili grlo | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| BR112012019374A2 (pt) | composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo | |
| JP2014218522A5 (enExample) | ||
| MX2021016109A (es) | Metodos y composiciones particularmente para el tratamiento del trastorno por deficit de atencion. | |
| BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
| JP2019530706A5 (enExample) | ||
| ES2681343T3 (es) | Composiciones para la mejora de la función cerebral | |
| JP2013501805A5 (enExample) | ||
| HRP20200142T1 (hr) | Postupci i sastavi za liječenje depresije uporabom ciklobenzaprina | |
| NZ754328A (en) | Marker for acid sphingomyelinase disorders and uses thereof | |
| JP2018039810A5 (enExample) | ||
| RU2016137926A (ru) | Композиции грапипранта и способы их применения | |
| HRP20211488T1 (hr) | Sastav i metoda za liječenje metaboličkih poremećaja | |
| HRP20230735T1 (hr) | Betahistin, ili njegova farmaceutski prihvatljiva sol, i inhibitor monoamin oksidaze, za uporabu u liječenju ili prevenciji jednog ili više simptoma vrtoglavice kod subjekta | |
| HRP20220701T1 (hr) | Spojeni benzazepini za liječenje touretteova sindroma |